Levogenix

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Levogenix

Quick Facts

Property Description
Active Ingredient Lansoprazol (INN)
Form Delayed-release capsules, Orally disintegrating tablets (ODT)
Pharmacological Class Proton Pump Inhibitor (PPI)
General Purpose Acid secretion suppression
Origin Synthetic pharmaceutical

What Type of Medicine is Levogenix?

Levogenix is a synthetic pharmaceutical classified by regulatory bodies as a Proton Pump Inhibitor (PPI), a highly effective type of Antisecretory drug designed to reduce acid levels within the stomach. Its active ingredient is Lansoprazol, a core compound belonging to the Substituted benzimidazole chemical class.

This medicine is intended for the management of conditions associated with pathological gastric acid hypersecretion, such as frequent, unwelcome acid reflux events. Lansoprazol is recognized for its efficacy in reducing gastric acid output. This classification, which targets the final step of acid production, enables a profound and sustained irreversible inhibition of acid secretion in the gastric parietal cells.


Composition, Origin, and Available Forms

Levogenix is a single active ingredient product containing Lansoprazol, formulated primarily for Oral administration in the form of Delayed-release capsules or Orally disintegrating tablets (ODT). The ODT formulation offers a practical option for patients who may have difficulty swallowing the capsules.

The essential delayed-release characteristic of these drug forms is mandatory. This design ensures that Lansoprazol is protected from the stomach's harsh acidic environment by an inert pharmaceutical vehicle until it passes into the intestine for proper absorption, where it becomes active. This mechanism of action is clinically recognized for its reliable delivery. This protection is necessary for the drug to reach its target, ensuring it can effectively inhibit the proton pump and perform its necessary antisecretory effect.


What is the General Purpose of a Proton Pump Inhibitor?

As a Proton Pump Inhibitor, the general purpose of Levogenix is to provide effective, sustained relief by mitigating the adverse effects of excessive acidity in the gastrointestinal tract. By performing comprehensive acid secretion suppression, the medicine manages issues arising from acid-related gastrointestinal disorders, creating a therapeutic environment that aids in overall symptom control.

What side effects are possible with Levogenix?

Possible side effects and safety information

Regulatory documents classify the possible side effects of Lansoprazol (Levogenix) based on frequency and the physiological systems affected. The most commonly documented adverse reactions, defined as occurring in 1% or more of patients in clinical trials, include effects on the gastrointestinal system, such as diarrhea, abdominal pain, nausea, and flatulence. Effects on the nervous system, such as headache and dizziness, are also classified as common.

Reactions categorized as uncommon include psychiatric disorders like depression, musculoskeletal effects like arthralgia (joint pain) and myalgia (muscle pain), and transient increases in liver enzyme levels. Certain blood and lymphatic system disorders, such as leucopenia, are also officially listed as uncommon.

Clinically Significant Safety Concerns

The official prescribing information addresses several potentially serious but less frequent concerns, particularly when the medicine is used long-term or at high doses. These include an increased risk of bone fracture (hip, wrist, or spine) and the potential development of hypomagnesemia (low magnesium levels) and Vitamin B12 deficiency, typically associated with extended daily therapy (e.g., one year or longer).

Regulatory labels also warn of rare but serious reactions, such as Acute Tubulointerstitial Nephritis (a form of kidney inflammation) and severe cutaneous adverse reactions (SCARs). For specific populations, caution is required in patients with severe hepatic impairment. Furthermore, symptom response to this medicine does not rule out the presence of an underlying gastric malignancy, as explicitly noted in official safety documentation.

Overdose and Emergency Response

The official regulatory documentation defines the overdose profile of Levogenix based on documented clinical manifestations and mandated emergency actions. The presentation of acute overexposure is differentiated by age. In adults, the chief manifestation reported is drowsiness or somnolence. Overdose presentation differs in children, where initial signs often include agitation or restlessness, which is subsequently followed by the development of drowsiness.

High-level ingestions—doses at least five times the daily recommended amount—have documented more severe clinical states, including stupor, confusion, and cardiovascular effects such as tachycardia. These documented effects confirm the potential for serious outcomes, even if such occurrences are rare.


Category Regulatory Statement
Immediate Action Required Patients must seek emergency medical attention or contact a Poison Control Center right away upon suspected overdose.
Antidote Status No known specific antidote is documented in the official prescribing information.
Management Measures Treatment focuses on symptomatic and supportive care. Gastric lavage should be considered following recent ingestion.
Removal Constraints The drug is not effectively removed by haemodialysis.

The overall overdose profile is strictly defined by these mandated emergency response requirements and the documented clinical symptom clusters, emphasizing that urgent medical help is required when overexposure is suspected.

Therapeutic Uses of Levogenix

What Levogenix Treats: Main Uses and Benefits

Levogenix (levocetirizine) is a second-generation antihistamine commonly used to help with symptoms related to heightened physiological activity caused by allergic reactions. It may assist with easing the overall symptom burden, which contributes to easing the overall symptom load during symptomatic periods.

Levogenix is applied in addressing conditions that involve recurrent or episodic manifestations. These conditions are perennial allergic rhinitis and the uncomplicated skin manifestations of chronic idiopathic urticaria (hives).

This medication is relevant for managing symptoms that interfere with daily comfort, such as sneezing, runny nose (rhinorrhea), and watery eyes from rhinitis, and is used in clinical scenarios where short-term symptomatic assistance is needed for skin discomfort. This application supports patients during episodes of heightened discomfort and assists with maintaining functional stability.

“Levogenix helps manage the discomfort and functional strain associated with common allergic reactions.”

Quick Fact: Relief for Symptoms that Interfere with Daily Functioning

Regulatory References

  1. National Institutes of Health (NIH) DailyMed product information

Eligibility and Restrictions for Use

Who Can and Cannot Use Levogenix?

Official regulatory guidelines strictly define the eligible patient population based primarily on renal function and known sensitivities.


Eligibility Scope

Classification Population Rule (Official Labeling)
Absolute Contraindication Patients with End-Stage Renal Disease ( CL CR < 10 mL/min) or who are undergoing hemodialysis are prohibited from use.
Hypersensitivity Prohibition Contraindicated for patients with known allergy to levocetirizine, its components, or related compounds like cetirizine or hydroxyzine.
Pediatric Restriction Children aged 6 months to 11 years with impaired renal function are formally contraindicated. The tablet formulation is not recommended for children under six years due to dosage limitations.
Conditional Use Use requires caution in patients with factors predisposing them to urinary retention (e.g., spinal cord lesion, prostatic hyperplasia).

Age- and Condition-Based Rules

Levogenix is approved for use in adults and adolescents (12 years and older) and children (6 months and older) with normal kidney function. Use in older adults with reduced renal function requires mandatory dose adjustment. For pregnant women, use may be considered if necessary. During lactation, the active substance is likely excreted in human milk, and the possibility of adverse reactions in the breastfed infant is noted.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes interactions officially documented in government regulatory sources for the active ingredient, Lansoprazol.

Contraindicated Combinations

Co-administration with Atazanavir and Rilpivirine is formally contraindicated. Levogenix significantly raises gastric pH, which reduces the absorption and systemic exposure of these antiretroviral agents.

Exposure-Modifying Interactions

The co-administration of Levogenix may affect the exposure of several co-medications.

  • Increased Concentrations: Levogenix may elevate and/or prolong the serum concentrations of Methotrexate, raising the potential for toxicity. Whole blood concentrations of Tacrolimus may also increase, requiring monitoring.
  • Decreased Efficacy: The efficacy of Clopidogrel may be decreased due to reduced formation of its active metabolite. Likewise, the absorption and bioavailability of drugs that require an acidic environment, such as Ketoconazole, Itraconazole, and Iron Salts, are diminished.

Other Documented Interaction Types

Co-administration with Warfarin requires monitoring of the International Normalized Ratio (INR) and prothrombin time. Similarly, the clearance of Theophylline may be altered, necessitating concentration monitoring. Furthermore, long-term daily use of Lansoprazol is officially associated with the potential for Cyanocobalamin (Vitamin B12) malabsorption.

Mechanism of Action

Levogenix is a substituted benzimidazole compound that selectively accumulates in the acidic secretory canaliculi of gastric parietal cells. As a prodrug, Levogenix undergoes acid-catalyzed conversion within this low pH environment into its active sulfenamide form.

This active metabolite functions as an irreversible non-competitive inhibitor by forming stable covalent disulfide bonds with specific cysteine residues, primarily Cys813 and Cys321, on the extracellular surface of the H^+,K^+-ATPase enzyme. This enzyme, often termed the gastric proton pump, is the final common pathway for hydrochloric acid (HCl) secretion into the gastric lumen.

By covalently binding to and permanently deactivating the H^+,K^+-ATPase, Levogenix blocks the transmembrane exchange of luminal K^+ for intracellular H^+. This molecular blockade results in the sustained cessation of both basal and stimulated acid secretion, irrespective of the upstream physiological stimulus (e.g., histamine, acetylcholine, gastrin). The system-level physiological consequence is a dose-dependent, prolonged elevation of gastric intraluminal pH.

Dosage and Administration Information

Levogenix (Lansoprazole) is administered via the oral route using delayed-release capsules or orally disintegrating tablets (ODT). The integrity of the delayed-release formulation is crucial; therefore, patients are instructed not to crush, chew, or otherwise manipulate the capsule or ODT forms. An alternative exists for patients unable to swallow capsules: the contents may be emptied and sprinkled onto soft food like applesauce or mixed with specific fruit juices, and swallowed immediately.

A key administration principle is that Levogenix must be taken before eating, generally specified as 30 minutes prior to a meal. This timing is directed to ensure the medicine's activity is aligned with the physiological process of maximal acid production.

The dosing schedule is precisely defined according to the clinical scenario. Standard adult regimens typically involve 15 mg or 30 mg taken once daily (OD). In cases of pathological hypersecretory conditions, higher total daily doses may be necessary and are administered as divided doses.

The overall course of use is regulated, spanning either short-term treatment (e.g., 4 to 8 weeks for healing) or long-term maintenance therapy for prevention. Dose adjustments, such as a possible reduction to 15 mg once daily, may be indicated for patients diagnosed with severe hepatic impairment. If a dose is missed, it should be taken when remembered, unless the time is near the next scheduled dose, in which case the missed dose should be skipped to resume the regular schedule.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Levogenix

Evidence for Use in Perennial Allergic Rhinitis

Research has examined Levogenix for its use in individuals with perennial allergic rhinitis, a condition characterized by fluctuating or episodic manifestations of allergy symptoms. The main research consisted of short-term Randomized, Controlled Trials (RCTs), where the medicine was evaluated in comparison to an inactive substance (placebo) and other studied treatments. These studies typically monitored the effects over periods lasting up to several weeks.

The primary focus of this research was to evaluate changes in the Total Symptom Score (TSS), which is the way scientists measure symptoms like sneezing, runny nose, and eye discomfort. Research also examined outcomes reflecting daily functioning or activity level, monitoring patient-reported outcomes describing perceived discomfort and overall quality of life. The findings help contextualize how patients reported their experience over the short-term evaluation intervals, and the evidence contributes to the broader evidence landscape regarding how symptoms may evolve in observed populations.


Evidence for Use in Chronic Idiopathic Urticaria (Hives)

Levogenix was studied for its application in managing chronic idiopathic urticaria (hives), a condition involving periods of heightened symptoms and functional limitations. The research structure included pivotal, double-blind, placebo-controlled trials conducted across multiple centers. These studies were applied in research contexts involving fluctuating or unstable symptoms, with the aim of monitoring changes in specific outcomes related to physical discomfort.

The studies examined endpoints such as the severity and duration of pruritus (itching) and the size and frequency of the wheals (hives). Additionally, researchers monitored how symptoms changed over the study periods, using patient-reported outcomes to describe the perceived discomfort and outcomes reflecting daily functioning. Research describes how symptoms were monitored in the observed populations for the primary symptom axes. This research contributes to the broader evidence landscape regarding short-term changes in symptom patterns for this condition where symptoms may vary in intensity.


Long-Term Data and Follow-Up Periods

Research regarding Levogenix focuses heavily on research exploring short-term symptom changes. While the primary evidence is based on these short-term measurements, some extended studies were observed in periods up to six months. These longer studies were used in research exploring how symptoms change over time, particularly focusing on outcomes reflecting daily functioning. However, the long-term effects are not fully established, and data are still emerging regarding the durability of the observed short-term patterns over years.

Frequently Asked Questions (FAQ)

Common questions about Levogenix (FAQ)

Q: How quickly can a person expect to feel the effects of Levogenix?

Official product information indicates that relief of symptoms may be experienced as early as the first dose. However, for conditions like heartburn, the full therapeutic effect of the medicine is often achieved after between 1 to 4 days of continuous use.


Q: Are there any foods or supplements that should be avoided while taking Levogenix?

Official documents note that this medicine may diminish the absorption of certain compounds, such as iron salts, and may decrease their effectiveness. Additionally, regulatory-sourced tips for managing heartburn suggest avoiding specific substances, like alcohol or caffeine, as they are known to cause or worsen heartburn symptoms.


Q: Is Levogenix safe to use for older adults or seniors?

Levogenix is indicated for use in adult populations. Official guidance indicates that reduced kidney function in older adults may require dosage adjustments, as outlined in the prescribing information.


Q: Is it common to feel tired or fatigued when first starting Levogenix?

Fatigue or tiredness are not listed among the commonly documented adverse reactions identified in clinical trials. However, feelings of tiredness or drowsiness (somnolence) have been reported in the post-marketing experience. The precise frequency of these occurrences is currently not established through clinical trials.


Q: Can Levogenix affect my ability to drive or operate machinery?

Common side effects, such as dizziness, have been reported in the official product information. These effects may potentially impair the performance of skilled tasks, such as driving or operating machinery.


Q: Will Levogenix still work if I occasionally drink alcohol?

Official labeling for the over-the-counter form states that alcohol should be avoided. This is because alcohol is classified as a substance that may cause or worsen heartburn symptoms, potentially undermining the medicine's effect on those symptoms.


Q: What is the typical timeframe for initial improvement according to studies?

The documents indicate that initial relief of symptoms may be rapid, beginning from the first dose. Studies conducted on primary indications, such as duodenal ulcer and reflux esophagitis, typically monitor the full effects of the medicine over several weeks during the short-term treatment course.


Q: What kind of monitoring or blood work is typically needed while on Levogenix?

Regulatory documents indicate that monitoring may be required when Levogenix is taken with certain other drugs, such as Warfarin or Theophylline. Additionally, testing blood levels for Vitamin B12 and magnesium is noted as a consideration for patients on long-term daily therapy.


Q: What should I do if my symptoms don't seem to improve after starting Levogenix?

Official documentation suggests that if symptoms are not relieved within the designated treatment period, or if symptoms worsen while taking the medicine, a medical re-evaluation is warranted.


Q: Is the active ingredient in Levogenix available as a generic drug?

Yes, the active ingredient in Levogenix is lansoprazole. Regulatory product databases confirm that lansoprazole is available from multiple manufacturers under its generic name.


Q: What is the risk of dependence or addiction with Levogenix?

According to official regulatory documents, this medicine has been classified as having no DEA Schedule. This means the drug is not officially listed as a controlled substance with a potential for abuse or dependence.


Q: Is it normal to have vivid dreams or sleep disturbances when taking Levogenix?

Adverse reactions related to sleep, such as abnormal dreams and sleep disorder, have been reported in the post-marketing experience. Official sources note these occurrences, but the precise frequency with which they happen has not been established in trials.


Q: What happens if Levogenix is taken with caffeine?

Official advice on managing heartburn symptoms suggests that substances like caffeine should be avoided. This is because caffeine may be more likely to cause or worsen the underlying heartburn symptoms.


Q: Why is this medication classified as a controlled substance (if applicable)?

This medicine is not classified as a controlled substance. Official regulatory documents list it as having no DEA Schedule.


Q: What are the general expectations for effectiveness when taking this drug?

As a Proton Pump Inhibitor, the medicine is intended for effective and sustained relief. Its general purpose is achieved through comprehensive suppression of acid secretion to mitigate the adverse effects of excessive acidity in the gastrointestinal tract.


Q: How does the research evidence compare to placebo in clinical trials?

Clinical trials for Levogenix were often structured as pivotal, double-blind, placebo-controlled trials. This means the medicine was formally evaluated against an inactive substance (placebo) to measure and monitor differences in symptom outcomes.


Q: Are there warnings about driving while taking Levogenix in the product information?

Official documents do not include a dedicated 'Driving Warning' section. However, common side effects such as dizziness have been reported. These effects may impair the performance of skilled tasks, such as driving.


Q: If I have a history of seizures, can I still use Levogenix?

Official safety documentation notes that long-term use is associated with a possible side effect of low magnesium levels (hypomagnesemia). This condition has been reported to cause serious effects, including seizures.


Q: How does Levogenix affect sleep patterns generally?

Adverse reactions related to sleep have been reported in post-marketing experience, including insomnia, somnolence (drowsiness), and sleep disorder. The frequency of these sleep-related effects has not been established in clinical trials.


Q: What is the purpose of the black box warning on Levogenix (if applicable)?

This medicine does not carry a Black Box Warning in its official FDA Prescribing Information. While it does not have this specific warning, the official document does contain several other important safety warnings and precautions.


Q: Can Levogenix cause temporary or permanent changes to vision?

Changes in vision have been reported in the post-marketing experience, specifically including blurred vision and abnormal vision. However, the frequency of these vision-related occurrences is not established in official documents.

How should Levogenix be stored and disposed of?

Levogenix (levofloxacin) should be stored correctly to maintain its effectiveness and safety. Keep the medicine in its original, tightly closed container and out of the reach of children and pets. The optimal storage conditions are generally at room temperature, typically between 68 F and 77 F (20 C and 25 C), protected from excessive heat, moisture, and direct light. Do not store this medication in a bathroom cabinet, where heat and humidity can be high.

Never use Levogenix after its expiration date. Proper disposal of unused or expired medicine is crucial to prevent accidental ingestion and environmental contamination. The best disposal method is often a community drug take-back program or an authorized collection site, such as those sometimes found at pharmacies or law enforcement facilities. If a take-back option is unavailable, you should follow the FDA's guidelines for disposal in household trash, which typically involves mixing the medicine with an undesirable substance like coffee grounds or cat litter, sealing the mixture in a container, and then discarding it.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Levogenix found in:

A-Z Index: